Calidi Biotherapeutics, Inc. financial data

Symbol
CLDI, CLDI-WT on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
4475 Executive Drive, Suite 200, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
First Light Acquisition Group, Inc. (to 9/19/2023)
Latest financial report
Q1 2024 - May 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 42.3 % +847%
Debt-to-equity -83 % -118%
Return On Equity 137 % +168%
Return On Assets -150 % -395%
Operating Margin -51.4 K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 35.5 M shares
Common Stock, Shares, Outstanding 35.7 M shares
Entity Public Float 43.3 M USD -81.1%
Common Stock, Value, Issued 4 K USD
Weighted Average Number of Shares Outstanding, Basic 35.6 M shares +311%
Weighted Average Number of Shares Outstanding, Diluted 35.6 M shares +311%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 45 K USD
Research and Development Expense 2.74 M USD +4.62%
Operating Income (Loss) -30.3 M USD -8.27%
Nonoperating Income (Expense) 367 K USD +55.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -30 M USD +10.1%
Income Tax Expense (Benefit) 16 K USD +6.67%
Net Income (Loss) Attributable to Parent -30 M USD -24.1%
Earnings Per Share, Basic -0.2 USD/shares +73.3%
Earnings Per Share, Diluted -0.2 USD/shares +73.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.2 M USD
Accounts Receivable, after Allowance for Credit Loss, Current 870 USD
Assets, Current 1.94 M USD +620%
Property, Plant and Equipment, Net 1.17 M USD
Operating Lease, Right-of-Use Asset 3.8 M USD -21.3%
Other Assets, Noncurrent 506 K USD
Assets 7.41 M USD -82.8%
Accounts Payable, Current 487 K USD +1652%
Accrued Liabilities, Current 5.79 M USD +1574%
Liabilities, Current 15 M USD +126%
Operating Lease, Liability, Noncurrent 2.76 M USD -27.4%
Other Liabilities, Noncurrent 1.5 M USD
Liabilities 22 M USD +170%
Accumulated Other Comprehensive Income (Loss), Net of Tax 11 K USD
Retained Earnings (Accumulated Deficit) -107 M USD -1255%
Stockholders' Equity Attributable to Parent -14.6 M USD +73.6%
Liabilities and Equity 7.41 M USD -82.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.83 M USD -23.3%
Net Cash Provided by (Used in) Financing Activities 3.01 M USD -20.5%
Net Cash Provided by (Used in) Investing Activities -5 K USD +96.4%
Common Stock, Shares Authorized 330 M shares
Common Stock, Shares, Issued 35.7 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -806 K USD -247%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.36 M USD +19.7%
Interest Paid, Excluding Capitalized Interest, Operating Activities 24 K USD +100%
Deferred Tax Assets, Valuation Allowance 23.9 M USD +53.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Cash and Cash Equivalents, Period Increase (Decrease) -465 K USD
Deferred Tax Assets, Gross 25 M USD +60.7%
Operating Lease, Liability 3.83 M USD -18.8%
Depreciation 102 K USD +9.68%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -7.17 M USD -10.9%
Lessee, Operating Lease, Liability, to be Paid 4.53 M USD
Property, Plant and Equipment, Gross 2.25 M USD
Operating Lease, Liability, Current 1.08 M USD +17%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.51 M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.47 M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 702 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 485 K USD
Deferred Tax Assets, Operating Loss Carryforwards 15.2 M USD +50.8%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) -922 K USD
Current Income Tax Expense (Benefit) 16 K USD +45.5%
Preferred Stock, Shares Authorized 1 M shares 0%
Unrecognized Tax Benefits 1.52 M USD +22.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3 K USD
Operating Lease, Payments 349 K USD +2.95%
Additional Paid in Capital 92.2 M USD
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 80.9 K USD
Current Federal Tax Expense (Benefit) 266 K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 888 K USD -38.1%
Deferred State and Local Income Tax Expense (Benefit) -208 K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%